 A pilot study with 23 EGFR M NSCLC patients demonstrated that the quantity of EGFR M in plasma correlates to the response to treatment and might be used to predict disease progression. In this study resistance mutations were detected between 20-300 days prior to clinical evidence of disease progression via CT scans. 